Obesity Market Report and Forecast 2025-2034
Description
The obesity market was valued at USD 16.90 Billion in 2024 driven by the rising obesity rates, sedentary lifestyles, and advancements in innovative therapeutic solutions across the 8 major markets. It is expected to grow at a CAGR of 10.10% during the forecast period of 2025-2034 and attain a market value of USD 44.23 Billion by 2034.
Obesity Market Overview
Obesity, influenced by sedentary lifestyles and poor dietary habits, significantly increases the risk of chronic diseases such as diabetes and cardiovascular disorders. Rising obesity prevalence worldwide is driving demand for effective management solutions. Key trends include increased awareness campaigns and advancements in digital healthcare and pharmaceutical innovations. These factors are reshaping the market, and encouraging the development of therapies, devices, and technologies to address this growing global health challenge.
Obesity Market Growth Drivers
Rising Prevalence of Obesity Boost the Market Demand
As per the World Obesity Federation 2023 report, around 51% or over 4.0 billion people globally are anticipated to live with obesity by 2035 (if measures are not taken at the time). This surge in prevalence, driven by sedentary lifestyles and poor dietary choices, is stimulating demand for obesity-related products and services. While wealthier nations often lead in health awareness initiatives, the growing global obesity crisis presents significant opportunities for companies to innovate and expand their offerings in health, nutrition, and wellness sectors.
Obesity Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Increasing Awareness to Drive Market Value
The increasing awareness around obesity is significantly influencing the market, as evidenced by the World Obesity Federation's 2023 campaign titled “Changing Perspectives: Let’s Talk About Obesity.” This initiative aimed to rectify misconceptions through constructive dialogue and promote healthier lifestyles. By addressing the stigma associated with obesity, the campaign sought to foster a more informed consumer base, encouraging demand for health-related products and services, and ultimately driving growth within the obesity management market.
Product Launches to Boost Obesity Market Growth
Strategic product launches are shaping the dynamics of the market. In June 2023, Eli Lilly and Company presented a phase 2 trial of retatrutide, revealing a substantial mean weight reduction of up to 24.2% over 48 weeks. This investigational drug also demonstrated significant improvements in key cardiometabolic markers, including blood pressure, cholesterol, and glucose levels. The TRIUMPH phase 3 trials promise to further assess retatrutide's efficacy, potentially transforming weight management and addressing obesity-related comorbidities.
Surge in Clinical Trials to Boost Obesity Market Value
The increasing incidence of clinical trials is poised to revolutionize the market by introducing groundbreaking treatments that promise significant therapeutic benefits. In May 2023, Innovent Biologics announced successful phase 2 results for mazdutide (9 mg), which demonstrated its efficacy in treating obesity among Chinese adults. The 24-week randomized, double-blind study, which included 80 participants, revealed a remarkable mean weight loss of -14.7 kg, corresponding to a -15.4% reduction from baseline, with 81.7% of subjects achieving a minimum of 5% weight loss, a statistic that highlights the drug’s potential market viability. The market anticipates further validation of this innovative approach, paving the way for new strategies to combat obesity and an expansion of therapeutic options for patients.
Digital Healthcare Solutions to Meet Increasing Obesity Market Demand
Digital healthcare solutions have significantly influenced the demand within the market by providing innovative and accessible care options. In January 2024, Eli Lilly launched LillyDirect™, a digital healthcare platform aimed at assisting United States patients in managing obesity, diabetes, and migraine. This platform integrated pharmacy solutions for home delivery, affordability resources, and telehealth access, thereby enhancing patient convenience and treatment outcomes. Lilly's initiative to expand LillyDirect with new adherence programs showcased a commitment to improving the comprehensive healthcare experience for patients, reflecting the growing intersection of technology and healthcare in addressing obesity.
Obesity Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Share by End User to Witness Significant Growth
Based on end users, the market is divided into speciality clinics, hospitals, beauty institutions, and others. Among these, hospitals are expected to dominate the market due to their comprehensive capabilities in addressing obesity through surgical interventions, medical therapies, and multidisciplinary approaches. Obesity-related comorbidities and a growing emphasis on integrated healthcare services are expected to bolster this segment. Additionally, hospitals are poised to drive substantial market growth during the forecast periods, leveraging advanced technologies and specialized care programs to enhance patient outcomes.
Obesity Market Analysis by Region
Regionally, the market is divided into the United States, United Kingdom, Germany, France, Italy, Spain, Japan and India. Among these, the United States is expected to dominate the market due to its well-established biopharmaceutical sector and several FDA approvals. For instance, in December 2024, the FDA approved Zepbound, a medication developed by Eli Lilly and Company, aimed at chronic weight management for individuals struggling with obesity or those who are overweight with related health issues. Zepbound operates by activating specific hormone receptors in the intestine, which helps to decrease appetite and food intake. Clinical evaluations conducted through two randomized controlled trials demonstrated that Zepbound leads to a statistically significant reduction in body weight, underscoring its effectiveness in promoting healthier weight management. The availability of such key players is likely to elevate market value in the forecast period.
Leading Players in the Obesity Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Johnson & Johnson Services, Inc.
Established in 1886 and headquartered in New Jersey, United States, Johnson & Johnson is a global leader in healthcare. The company offers medical devices such as gastric bands, which are used in bariatric surgeries for obesity treatment. These solutions aim to assist individuals in managing obesity effectively by providing innovative and minimally invasive medical technologies.
Apollo Endosurgery, Inc.
Now a part of Boston Scientific, Apollo Endosurgery specialises in developing minimally invasive medical devices aimed at advancing therapeutic endoscopy, particularly for managing obesity. Their product portfolio includes the ORBERA® Intragastric Balloon System, a non-surgical weight loss solution, and the OverStitch™ Endoscopic Suturing System, which facilitates a range of less invasive procedures by enabling secure, full-thickness sutures through a flexible endoscope.
Novo Nordisk A/S
Formed in 1923 and headquartered in Denmark, Novo Nordisk A/S focuses on innovative treatments for obesity. Its portfolio includes drugs like Saxenda (liraglutide) and Wegovy (semaglutide), which aid in weight loss and management by regulating appetite. Novo Nordisk is recognized globally for its commitment to addressing obesity and associated health challenges through groundbreaking therapies.
AbbVie Incorporation
Established in 2012 and headquartered in North Chicago, Illinois, AbbVie is dedicated to advancing metabolic research, including potential treatments for obesity. While specific drugs are under development, AbbVie focuses on innovative therapeutic approaches to tackle obesity-related conditions, reflecting its commitment to improving patient outcomes in the field of metabolic and chronic diseases.
Other key players in the market include Arena Pharmaceuticals Inc., Atkins Nutritionals, Ltd., Brunswick Corporation, C.H. Boehringer Sohn AG & Ko. KG, EnteroMedics Incorporation, F. Hoffmann-La Roche Ltd, Herbalife Ltd, Orexigen Therapeutics Inc., and NutriSystem Incorporation.
Key Questions Answered in the Obesity Market
Obesity Market Overview
Obesity, influenced by sedentary lifestyles and poor dietary habits, significantly increases the risk of chronic diseases such as diabetes and cardiovascular disorders. Rising obesity prevalence worldwide is driving demand for effective management solutions. Key trends include increased awareness campaigns and advancements in digital healthcare and pharmaceutical innovations. These factors are reshaping the market, and encouraging the development of therapies, devices, and technologies to address this growing global health challenge.
Obesity Market Growth Drivers
Rising Prevalence of Obesity Boost the Market Demand
As per the World Obesity Federation 2023 report, around 51% or over 4.0 billion people globally are anticipated to live with obesity by 2035 (if measures are not taken at the time). This surge in prevalence, driven by sedentary lifestyles and poor dietary choices, is stimulating demand for obesity-related products and services. While wealthier nations often lead in health awareness initiatives, the growing global obesity crisis presents significant opportunities for companies to innovate and expand their offerings in health, nutrition, and wellness sectors.
Obesity Market Trends
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
Increasing Awareness to Drive Market Value
The increasing awareness around obesity is significantly influencing the market, as evidenced by the World Obesity Federation's 2023 campaign titled “Changing Perspectives: Let’s Talk About Obesity.” This initiative aimed to rectify misconceptions through constructive dialogue and promote healthier lifestyles. By addressing the stigma associated with obesity, the campaign sought to foster a more informed consumer base, encouraging demand for health-related products and services, and ultimately driving growth within the obesity management market.
Product Launches to Boost Obesity Market Growth
Strategic product launches are shaping the dynamics of the market. In June 2023, Eli Lilly and Company presented a phase 2 trial of retatrutide, revealing a substantial mean weight reduction of up to 24.2% over 48 weeks. This investigational drug also demonstrated significant improvements in key cardiometabolic markers, including blood pressure, cholesterol, and glucose levels. The TRIUMPH phase 3 trials promise to further assess retatrutide's efficacy, potentially transforming weight management and addressing obesity-related comorbidities.
Surge in Clinical Trials to Boost Obesity Market Value
The increasing incidence of clinical trials is poised to revolutionize the market by introducing groundbreaking treatments that promise significant therapeutic benefits. In May 2023, Innovent Biologics announced successful phase 2 results for mazdutide (9 mg), which demonstrated its efficacy in treating obesity among Chinese adults. The 24-week randomized, double-blind study, which included 80 participants, revealed a remarkable mean weight loss of -14.7 kg, corresponding to a -15.4% reduction from baseline, with 81.7% of subjects achieving a minimum of 5% weight loss, a statistic that highlights the drug’s potential market viability. The market anticipates further validation of this innovative approach, paving the way for new strategies to combat obesity and an expansion of therapeutic options for patients.
Digital Healthcare Solutions to Meet Increasing Obesity Market Demand
Digital healthcare solutions have significantly influenced the demand within the market by providing innovative and accessible care options. In January 2024, Eli Lilly launched LillyDirect™, a digital healthcare platform aimed at assisting United States patients in managing obesity, diabetes, and migraine. This platform integrated pharmacy solutions for home delivery, affordability resources, and telehealth access, thereby enhancing patient convenience and treatment outcomes. Lilly's initiative to expand LillyDirect with new adherence programs showcased a commitment to improving the comprehensive healthcare experience for patients, reflecting the growing intersection of technology and healthcare in addressing obesity.
Obesity Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Surgery
- Biliopancreatic diversion with Duodenal Switch (BPD/DS)
- Adjusting Gastric Banding
- Roux-en-Y Gastric Bypass
- Sleeve Gastrectomy
- Endoscopic Procedures
- Drugs
- Appetite suppressants
- Combination drugs
- Malabsorption
- Satiety drugs
- Nutritional Product
- Speciality Clinics
- Hospitals
- Beauty Institutions
- Others
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Market Share by End User to Witness Significant Growth
Based on end users, the market is divided into speciality clinics, hospitals, beauty institutions, and others. Among these, hospitals are expected to dominate the market due to their comprehensive capabilities in addressing obesity through surgical interventions, medical therapies, and multidisciplinary approaches. Obesity-related comorbidities and a growing emphasis on integrated healthcare services are expected to bolster this segment. Additionally, hospitals are poised to drive substantial market growth during the forecast periods, leveraging advanced technologies and specialized care programs to enhance patient outcomes.
Obesity Market Analysis by Region
Regionally, the market is divided into the United States, United Kingdom, Germany, France, Italy, Spain, Japan and India. Among these, the United States is expected to dominate the market due to its well-established biopharmaceutical sector and several FDA approvals. For instance, in December 2024, the FDA approved Zepbound, a medication developed by Eli Lilly and Company, aimed at chronic weight management for individuals struggling with obesity or those who are overweight with related health issues. Zepbound operates by activating specific hormone receptors in the intestine, which helps to decrease appetite and food intake. Clinical evaluations conducted through two randomized controlled trials demonstrated that Zepbound leads to a statistically significant reduction in body weight, underscoring its effectiveness in promoting healthier weight management. The availability of such key players is likely to elevate market value in the forecast period.
Leading Players in the Obesity Market
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Johnson & Johnson Services, Inc.
Established in 1886 and headquartered in New Jersey, United States, Johnson & Johnson is a global leader in healthcare. The company offers medical devices such as gastric bands, which are used in bariatric surgeries for obesity treatment. These solutions aim to assist individuals in managing obesity effectively by providing innovative and minimally invasive medical technologies.
Apollo Endosurgery, Inc.
Now a part of Boston Scientific, Apollo Endosurgery specialises in developing minimally invasive medical devices aimed at advancing therapeutic endoscopy, particularly for managing obesity. Their product portfolio includes the ORBERA® Intragastric Balloon System, a non-surgical weight loss solution, and the OverStitch™ Endoscopic Suturing System, which facilitates a range of less invasive procedures by enabling secure, full-thickness sutures through a flexible endoscope.
Novo Nordisk A/S
Formed in 1923 and headquartered in Denmark, Novo Nordisk A/S focuses on innovative treatments for obesity. Its portfolio includes drugs like Saxenda (liraglutide) and Wegovy (semaglutide), which aid in weight loss and management by regulating appetite. Novo Nordisk is recognized globally for its commitment to addressing obesity and associated health challenges through groundbreaking therapies.
AbbVie Incorporation
Established in 2012 and headquartered in North Chicago, Illinois, AbbVie is dedicated to advancing metabolic research, including potential treatments for obesity. While specific drugs are under development, AbbVie focuses on innovative therapeutic approaches to tackle obesity-related conditions, reflecting its commitment to improving patient outcomes in the field of metabolic and chronic diseases.
Other key players in the market include Arena Pharmaceuticals Inc., Atkins Nutritionals, Ltd., Brunswick Corporation, C.H. Boehringer Sohn AG & Ko. KG, EnteroMedics Incorporation, F. Hoffmann-La Roche Ltd, Herbalife Ltd, Orexigen Therapeutics Inc., and NutriSystem Incorporation.
Key Questions Answered in the Obesity Market
- What was the obesity market value in 2024?
- What is the obesity market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is the market segmentation based on the type?
- What is the market segmentation based on the end user?
- What are the major factors aiding the obesity market demand?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major obesity market trends?
- How does the rise in the geriatric population impact the market size?
- Who are the key players involved in the obesity market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Obesity Market Overview – 8 Major Markets
- 3.1 Obesity Market Historical Value (2018-2024)
- 3.2 Obesity Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Obesity Market: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Obesity Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 Germany
- 7.2.4 France
- 7.2.5 Italy
- 7.2.6 Spain
- 7.2.7 India
- 7.2.8 Japan
- 7.3 Diagnosed Cases, by Country
- 7.3.1 United States
- 7.3.2 United Kingdom
- 7.3.3 Germany
- 7.3.4 France
- 7.3.5 Italy
- 7.3.6 Spain
- 7.3.7 India
- 7.3.8 Japan
- 7.4 Treatment Seeking Rate, by Country
- 7.4.1 United States
- 7.4.2 United Kingdom
- 7.4.3 Germany
- 7.4.4 France
- 7.4.5 Italy
- 7.4.6 Spain
- 7.4.7 India
- 7.4.8 Japan
- 8 Obesity Market Landscape – 8 Major Markets
- 8.1 Obesity Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Obesity Market: Product Landscape
- 8.2.1 Analysis By Treatment Type
- 8.2.2 Analysis By Drug Type
- 9 Obesity Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Obesity Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Obesity Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Obesity Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Surgery
- 12.1.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS)
- 12.1.2.2 Adjusting Gastric Banding
- 12.1.2.3 Roux-en-Y Gastric Bypass
- 12.1.2.4 Sleeve Gastrectomy
- 12.1.2.5 Endoscopic Procedures
- 12.1.3 Drugs
- 12.1.3.1 Appetite suppressants
- 12.1.3.2 Combination drugs
- 12.1.3.3 Malabsorption
- 12.1.3.4 Satiety drugs
- 12.1.4 Nutritional Product
- 12.2 Obesity Market (2018-2034) by End User
- 12.2.1 Market Overview
- 12.2.2 Specialty Clinics
- 12.2.3 Hospitals
- 12.2.4 Beauty Institutions
- 12.2.5 Others
- 12.3 Obesity Market (2018-2034) by Region
- 12.3.1 Market Overview
- 12.3.2 United States
- 12.3.3 United Kingdom
- 12.3.4 Germany
- 12.3.5 France
- 12.3.6 Italy
- 12.3.7 Spain
- 12.3.8 Japan
- 12.3.9 India
- 13 United States Obesity Market (218-2034)
- 13.1 United States Obesity Market (2018-2034) by Type
- 13.1.1 Market Overview
- 13.1.2 Surgery
- 13.1.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS)
- 13.1.2.2 Adjusting Gastric Banding
- 13.1.2.3 Roux-en-Y Gastric Bypass
- 13.1.2.4 Sleeve Gastrectomy
- 13.1.2.5 Endoscopic Procedures
- 13.1.3 Drugs
- 13.1.3.1 Appetite suppressants
- 13.1.3.2 Combination drugs
- 13.1.3.3 Malabsorption
- 13.1.3.4 Satiety drugs
- 13.1.4 Nutritional Product
- 13.2 United States Obesity Market (2018-2034) by End User
- 13.2.1 Market Overview
- 13.2.2 Specialty Clinics
- 13.2.3 Hospitals
- 13.2.4 Beauty Institutions
- 13.2.5 Others
- 14 United Kingdom Obesity Market (218-2034)
- 14.1 United Kingdom Obesity Market (2018-2034) by Type
- 14.1.1 Market Overview
- 14.1.2 Surgery
- 14.1.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS)
- 14.1.2.2 Adjusting Gastric Banding
- 14.1.2.3 Roux-en-Y Gastric Bypass
- 14.1.2.4 Sleeve Gastrectomy
- 14.1.2.5 Endoscopic Procedures
- 14.1.3 Drugs
- 14.1.3.1 Appetite suppressants
- 14.1.3.2 Combination drugs
- 14.1.3.3 Malabsorption
- 14.1.3.4 Satiety drugs
- 14.1.4 Nutritional Product
- 14.2 United Kingdom Obesity Market (2018-2034) by End User
- 14.2.1 Market Overview
- 14.2.2 Specialty Clinics
- 14.2.3 Hospitals
- 14.2.4 Beauty Institutions
- 14.2.5 Others
- 15 Germany Obesity Market (218-2034)
- 15.1 Germany Obesity Market (2018-2034) by Type
- 15.1.1 Market Overview
- 15.1.2 Surgery
- 15.1.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS)
- 15.1.2.2 Adjusting Gastric Banding
- 15.1.2.3 Roux-en-Y Gastric Bypass
- 15.1.2.4 Sleeve Gastrectomy
- 15.1.2.5 Endoscopic Procedures
- 15.1.3 Drugs
- 15.1.3.1 Appetite suppressants
- 15.1.3.2 Combination drugs
- 15.1.3.3 Malabsorption
- 15.1.3.4 Satiety drugs
- 15.1.4 Nutritional Product
- 15.2 Germany Obesity Market (2018-2034) by End User
- 15.2.1 Market Overview
- 15.2.2 Specialty Clinics
- 15.2.3 Hospitals
- 15.2.4 Beauty Institutions
- 15.2.5 Others
- 16 France Obesity Market (218-2034)
- 16.1 France Obesity Market (2018-2034) by Type
- 16.1.1 Market Overview
- 16.1.2 Surgery
- 16.1.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS)
- 16.1.2.2 Adjusting Gastric Banding
- 16.1.2.3 Roux-en-Y Gastric Bypass
- 16.1.2.4 Sleeve Gastrectomy
- 16.1.2.5 Endoscopic Procedures
- 16.1.3 Drugs
- 16.1.3.1 Appetite suppressants
- 16.1.3.2 Combination drugs
- 16.1.3.3 Malabsorption
- 16.1.3.4 Satiety drugs
- 16.1.4 Nutritional Product
- 16.2 France Obesity Market (2018-2034) by End User
- 16.2.1 Market Overview
- 16.2.2 Specialty Clinics
- 16.2.3 Hospitals
- 16.2.4 Beauty Institutions
- 16.2.5 Others
- 17 Italy Obesity Market (218-2034)
- 17.1 Italy Obesity Market (2018-2034) by Type
- 17.1.1 Market Overview
- 17.1.2 Surgery
- 17.1.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS)
- 17.1.2.2 Adjusting Gastric Banding
- 17.1.2.3 Roux-en-Y Gastric Bypass
- 17.1.2.4 Sleeve Gastrectomy
- 17.1.2.5 Endoscopic Procedures
- 17.1.3 Drugs
- 17.1.3.1 Appetite suppressants
- 17.1.3.2 Combination drugs
- 17.1.3.3 Malabsorption
- 17.1.3.4 Satiety drugs
- 17.1.4 Nutritional Product
- 17.2 Italy Obesity Market (2018-2034) by End User
- 17.2.1 Market Overview
- 17.2.2 Specialty Clinics
- 17.2.3 Hospitals
- 17.2.4 Beauty Institutions
- 17.2.5 Others
- 18 Spain Obesity Market (218-2034)
- 18.1 Spain Obesity Market (2018-2034) by Type
- 18.1.1 Market Overview
- 18.1.2 Surgery
- 18.1.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS)
- 18.1.2.2 Adjusting Gastric Banding
- 18.1.2.3 Roux-en-Y Gastric Bypass
- 18.1.2.4 Sleeve Gastrectomy
- 18.1.2.5 Endoscopic Procedures
- 18.1.3 Drugs
- 18.1.3.1 Appetite suppressants
- 18.1.3.2 Combination drugs
- 18.1.3.3 Malabsorption
- 18.1.3.4 Satiety drugs
- 18.1.4 Nutritional Product
- 18.2 Spain Obesity Market (2018-2034) by End User
- 18.2.1 Market Overview
- 18.2.2 Specialty Clinics
- 18.2.3 Hospitals
- 18.2.4 Beauty Institutions
- 18.2.5 Others
- 19 Japan Obesity Market (218-2034)
- 19.1 Japan Obesity Market (2018-2034) by Type
- 19.1.1 Market Overview
- 19.1.2 Surgery
- 19.1.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS)
- 19.1.2.2 Adjusting Gastric Banding
- 19.1.2.3 Roux-en-Y Gastric Bypass
- 19.1.2.4 Sleeve Gastrectomy
- 19.1.2.5 Endoscopic Procedures
- 19.1.3 Drugs
- 19.1.3.1 Appetite suppressants
- 19.1.3.2 Combination drugs
- 19.1.3.3 Malabsorption
- 19.1.3.4 Satiety drugs
- 19.1.4 Nutritional Product
- 19.2 Japan Obesity Market (2018-2034) by End User
- 19.2.1 Market Overview
- 19.2.2 Specialty Clinics
- 19.2.3 Hospitals
- 19.2.4 Beauty Institutions
- 19.2.5 Others
- 20 India Obesity Market (218-2034)
- 20.1 India Obesity Market (2018-2034) by Type
- 20.1.1 Market Overview
- 20.1.2 Surgery
- 20.1.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS)
- 20.1.2.2 Adjusting Gastric Banding
- 20.1.2.3 Roux-en-Y Gastric Bypass
- 20.1.2.4 Sleeve Gastrectomy
- 20.1.2.5 Endoscopic Procedures
- 20.1.3 Drugs
- 20.1.3.1 Appetite suppressants
- 20.1.3.2 Combination drugs
- 20.1.3.3 Malabsorption
- 20.1.3.4 Satiety drugs
- 20.1.4 Nutritional Product
- 20.2 India Obesity Market (2018-2034) by End User
- 20.2.1 Market Overview
- 20.2.2 Specialty Clinics
- 20.2.3 Hospitals
- 20.2.4 Beauty Institutions
- 20.2.5 Others
- 21 Regulatory Framework
- 21.1 Regulatory Overview
- 21.2 US FDA
- 21.3 EU EMA
- 21.4 Japan PMDA
- 21.5 India CDSCO
- 21.6 Others
- 22 Patent Analysis
- 22.1 Analysis by Type of Patent
- 22.2 Analysis by Publication Year
- 22.3 Analysis by Issuing Authority
- 22.4 Analysis by Patent Age
- 22.5 Analysis by CPC Analysis
- 22.6 Analysis by Patent Valuation
- 23 Clinical Trials Analysis
- 23.1 Analysis by Trial Registration Year
- 23.2 Analysis by Trial Status
- 23.3 Analysis by Trial Phase
- 23.4 Analysis by Therapeutic Area
- 23.5 Analysis by Geography
- 24 Grants Analysis
- 24.1 Analysis by Year
- 24.2 Analysis by Amount Awarded
- 24.3 Analysis by Issuing Authority
- 24.4 Analysis by Grant Application
- 24.5 Analysis by Funding Institute
- 24.6 Analysis by NIH Departments
- 24.7 Analysis by Recipient Organization
- 25 Funding and Investment Analysis
- 25.1 Analysis by Funding Instances
- 25.2 Analysis by Drug Class of Funding
- 25.3 Analysis by Funding Amount
- 25.4 Analysis by Leading Players
- 25.5 Analysis by Leading Investors
- 25.6 Analysis by Geography
- 26 Strategic Initiatives
- 26.1 Analysis by Partnership Instances
- 26.2 Analysis by Drug Class of Partnership
- 26.3 Analysis by Leading Players
- 26.4 Analysis by Geography
- 27 Supplier Landscape
- 27.1 Market Share Analysis, By Region (Top 5 Companies)
- 27.2 AbbVie Incorporation
- 27.2.1 Financial Analysis
- 27.2.2 Product Portfolio
- 27.2.3 Demographic Reach and Achievements
- 27.2.4 Company News and Development
- 27.2.5 Certifications
- 27.3 Apollo Endosurgery, Inc.
- 27.3.1 Financial Analysis
- 27.3.2 Product Portfolio
- 27.3.3 Demographic Reach and Achievements
- 27.3.4 Company News and Development
- 27.3.5 Certifications
- 27.4 Arena Pharmaceuticals Inc.
- 27.4.1 Financial Analysis
- 27.4.2 Product Portfolio
- 27.4.3 Demographic Reach and Achievements
- 27.4.4 Company News and Development
- 27.4.5 Certifications
- 27.5 Atkins Nutritionals, Ltd.
- 27.5.1 Financial Analysis
- 27.5.2 Product Portfolio
- 27.5.3 Demographic Reach and Achievements
- 27.5.4 Company News and Development
- 27.5.5 Certifications
- 27.6 Brunswick Corporation
- 27.6.1 Financial Analysis
- 27.6.2 Product Portfolio
- 27.6.3 Demographic Reach and Achievements
- 27.6.4 Company News and Development
- 27.6.5 Certifications
- 27.7 C.H. Boehringer Sohn AG & Ko. KG
- 27.7.1 Financial Analysis
- 27.7.2 Product Portfolio
- 27.7.3 Demographic Reach and Achievements
- 27.7.4 Company News and Development
- 27.7.5 Certifications
- 27.8 EnteroMedics, Incorporation
- 27.8.1 Financial Analysis
- 27.8.2 Product Portfolio
- 27.8.3 Demographic Reach and Achievements
- 27.8.4 Company News and Development
- 27.8.5 Certifications
- 27.9 F. Hoffmann-La Roche, Ltd
- 27.9.1 Financial Analysis
- 27.9.2 Product Portfolio
- 27.9.3 Demographic Reach and Achievements
- 27.9.4 Company News and Development
- 27.9.5 Certifications
- 27.10 Herbalife Ltd
- 27.10.1 Financial Analysis
- 27.10.2 Product Portfolio
- 27.10.3 Demographic Reach and Achievements
- 27.10.4 Company News and Development
- 27.10.5 Certifications
- 27.11 Johnson & Johnson Services, Inc.
- 27.11.1 Financial Analysis
- 27.11.2 Product Portfolio
- 27.11.3 Demographic Reach and Achievements
- 27.11.4 Company News and Development
- 27.11.5 Certifications
- 27.12 Novo Nordisk A/S
- 27.12.1 Financial Analysis
- 27.12.2 Product Portfolio
- 27.12.3 Demographic Reach and Achievements
- 27.12.4 Company News and Development
- 27.12.5 Certifications
- 27.13 NutriSystem, Incorporation
- 27.13.1 Financial Analysis
- 27.13.2 Product Portfolio
- 27.13.3 Demographic Reach and Achievements
- 27.13.4 Company News and Development
- 27.13.5 Certifications
- 27.14 Orexigen Therapeutics, Inc.
- 27.14.1 Financial Analysis
- 27.14.2 Product Portfolio
- 27.14.3 Demographic Reach and Achievements
- 27.14.4 Company News and Development
- 27.14.5 Certifications
- 28 Obesity Market - Distribution Model (Additional Insight)
- 28.1 Overview
- 28.2 Potential Distributors
- 28.3 Key Parameters for Distribution Partner Assessment
- 29 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 30 Payment Methods (Additional Insight)
- 30.1 Government Funded
- 30.2 Private Insurance
- 30.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
